ISSN 0169-5002
Publisher: Elsevier
< previous issue | all issues | next issue >
The plasminogen activation system and its role in lung cancer. A review pp. 1-12(12) Authors: Pappot H.; Brunner N.
Establishment and characterization of a new human lung poorly differentiated adenocarcinoma cell line, GLL-1, producing carcinoembryonic antigen (CEA) and CA19-9 pp. 13-24(12) Authors: Mitsuhashi N.; Takahashi T.; Sakurai H.; Yamakawa M.; Hasegawa M.; Furuta M.; Matsumoto H.; Higuchi K.; Hayakawa K.; Niibe H.
Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients pp. 25-34(10) Authors: Tammilehto L.; Kivisaari L.; Salminen U.-S.; Maasilta P.; Mattson K.
Bronchoscopic findings of extramural lung cancer invading the subepithelium or submucosa pp. 35-44(10) Authors: Gemma A.; Takenaka K.; Andou M.; Yamada K.; Hasegawa K.; Tachibana M.; Iwanami H.; Sakonji M.; Tsuboi E.; Kudoh S.; Niitani H.
The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer pp. 45-58(14) Authors: Buccheri G.F.; Ferrigno D.; Tamburini M.; Brunelli C.
Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer pp. 59-65(7) Authors: Miller A.A.; Niell H.B.; Griffin J.P.
Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer pp. 67-76(10) Authors: Espinosa E.; Feliu J.; Zamora P.; Baron M.G.; Sanchez J.J.; Ordonez A.; Espinosa J.
Tracheal obstruction after placement of a metal wire expandable stent (Wallstent) pp. 77-80(4) Authors: Koster M.E.Y.; Baas P.; Wagenaar J.P.M.; van Zandwijk N.
Fatal pulmonary toxicity following oral etoposide therapy pp. 81-86(6) Authors: Dajczman E.; Srolovitz H.; Kreisman H.; Frank H.
Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop pp. 91-103(13) Authors: Battey J.F.; Brown P.H.; Gritz E.R.; Hong W.K.; Johnson B.E.; Karp D.D.; Mulshine J.L.; Shaw G.L.; Shopland D.R.; Sunday M.E.; Szabo E.
Cuneo Lung Cancer Study Group First International Lung Cancer Conference: Non-small cell lung cancer: Open questions and controversies pp. 105-108(4) Author: Buccheri G.
Environmental tobacco smoke and lung cancer in nonsmoking women: A multicenter study pp. 113-113(1) Authors: Fontham E.; Correa P.; Reynolds P.; Wu-Williams A.; Buffler P.; Greenberg R.
The Alpha-Tocopherol, Beta-Carotene cancer prevention study in Finland pp. 113-113(1) Authors: Blumberg J.; Block G.
Inconsistency between workplace and spousal studies of environmental tobacco smoke and lung cancer pp. 113-113(1) Authors: LeVois M.; Layard M.
Declining FEV1 and chronic productive cough in cigarette smokers: A 25- year prospective study of lung cancer incidence in Tecumseh, Michigan pp. 113-114(2) Authors: Islam S.; Schottenfeld D.
Smoking and cancer: Smoking cessation pp. 114-114(1) Authors: Austoker J.; Sanders D.; Fowler G.
Case-Control study for lung cancer and cigarette smoking in Osaka, Japan: Comparison with the results from Western Europe pp. 114-114(1) Authors: Sobue T.; Suzuki T.; Fujimoto I.; Matsuda M.; Doi O.; Mori T.
Asbestos exposure and the risk of lung cancer in a general urban population pp. 114-114(1) Authors: Karjalainen A.; Anttila S.; Vanhala E.; Vainio H.
Smoking of hand-rolled cigarettes as a risk factor for small cell lung cancer in men: A case-control study from Uruguay pp. 115-115(1) Authors: De Stefani E.; Fierro L.; Larrinaga M.; Balbi J.; Ronco A.; Mendilaharsu M.
Risk factors for lung cancer in Rio de Janeiro, Brazil: A case-control study pp. 115-115(1) Authors: Suzuki I.; Hamada G.; Zambonic M.; De Biasi Cordeiro P.; Watanabe S.; Tsugane S.
A case-control study of diet and lung cancer in Kerala, South India pp. 115-115(1) Authors: Sankaranayanan R.; Varghese C.; Duffy S.; Padmakumary G.; Day N.; Nair M.
A study of autopsied lung cancer cases among retired workers of the Okuno-jima poison gas factory pp. 115-115(1) Authors: Maeda A.; Awaya Y.; Ihara Y.; Yoshida Y.; Ishioka S.; Inamizu T.
Human evidence: Lung cancer mortality risk from chrysotile exposure pp. 115-116(2) Author: Hughes J.
Lung cancer mortality among asbestos textile workers: A review and update pp. 116-116(1) Authors: Dement J.; Brown D.
Case-control study of residential radon and lung cancer in Winnipeg, Manitoba, Canada pp. 116-116(1) Authors: Letourneau E.; Krewski D.; Choi N.; Goddard M.; McGregor R.; Zielinski J.
Genetic component of lung cancer: Cohort study of twins pp. 116-116(1) Authors: Braun M.; Caporaso N.; Page W.; Hoover R.
Contribution of cadmium in cigarettes to lung cancer: An evaluation of risk assessment methodologies pp. 116-116(1) Authors: Hertz-Picciotto I.; Hu S.-W.
Correlating exposure to environmental tobacco smoke exposure with increased incidence of lung cancer in non smokers: Is continine a valid marker? pp. 116-117(2) Author: Roberfroid M.
Recent results and open questions of health hazards by radon with special consideration of the ''Schneeberger lung disease'' pp. 117-117(1) Authors: Laussmann D.; Arndt D.; Mehnert W.
Residental radon exposure and lung cancer - An epidemiological study of Norwegian municipalities pp. 117-117(1) Authors: Magnus K.; Engeland A.; Green B.; Haldorsen T.; Muirhead C.; Strand T.
Higher lung cancer rates in young women than young men: Tasmania, 1983 to 1992 pp. 117-117(1) Authors: Dwyer T.; Blizzard L.; Shugg D.; Hill D.; Ansari M.
Cohort mortality and nested case-control study of lung cancer among structural pest control workers in Florida (United States) pp. 117-117(1) Authors: Pesatori A.; Sontag J.; Lubin J.; Consonni D.; Blair A.
Characteristics of chromate workers' cancers, chromium lung deposition and precancerous bronchial lesions: An autopsy study pp. 118-118(1) Authors: Ishikawa Y.; Nakagawa K.; Satoh Y.; Kitagawa T.; Sugano H.; Hirano T.
Exposure to radon progeny, tobacco use and lung cancer in a case-control study in southern China pp. 118-118(1) Authors: Shu X.; Yao Lubin J.; You Lin Q.; Boice J.; Jun Yao L.; Shu Kan C.
Histology and smoking history of lung cancer cases and implications for prevention in Thailand pp. 118-118(1) Authors: Limsila T.; Mitacek E.; Caplan L.; Brunnemann K.
Lung cancer risk and welding - Preliminary results from an ongoing case-control study pp. 118-118(1) Authors: Jockel K.-H.; Ahrens W.; Bolm-Audorff U.
Exposure to stainless steel welding fumes and lung cancer: A meta-analysis pp. 118-119(2) Authors: Sjogren B.; Hansen K.; Kjuus H.; Persson P.-G.
Contemporary situation of screening and primary prevention in control of lung cancer pp. 119-119(1) Author: Kubik A.
Exposure and disposition in the development of lung cancer pp. 119-119(1) Author: Rudiger H.
Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines pp. 119-119(1) Authors: Sekido Y.; Bader S.; Carbone D.; Johnson B.; Minna J.
Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha- and beta-calcitonin gene related peptides pp. 119-119(1) Authors: Kelley M.; Sinder R.; Becker K.; Johnson B.
Integrin expression and ability to adhere to extracellular matrix proteins and endothelial cells in human lung cancer lines pp. 119-119(1) Authors: Hirasawa M.; Shijubo N.; Uede T.; Abe S.
Spontaneous production of interleukin-8 by human lung cancer cells and its augmentation by tumor necrosis factor alpha and interleukin-1 at protein and mRNA levels pp. 120-120(1) Authors: Mizuno K.; Sone S.; Orino E.; Mukaida N.; Matsushima K.; Ogura T.
Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer pp. 120-120(1) Authors: Kato S.; Shields P.; Caporaso N.; Sugimura H.; Trivers G.; Tucker M.
A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes pp. 120-120(1) Authors: Kok K.; Van den Berg A.; Veldhuis P.; Van der Veen A.; Franke M.; Schoenmakers E.
5-HT(1D) receptor type is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma pp. 120-120(1) Authors: Cattaneo M.; Palazzi E.; Bondiolotti G.; Vincenti L.
Analysis of urinary fibronectin (UFN) using human lung cancer cells transplanted into nude mice pp. 120-120(1) Authors: Nonaka M.; Kadokura M.; Tanio N.; Yamamoto S.; Takaba T.
Establishment of a new lung sarcoma cell line from a human lung carcinosarcoma pp. 120-121(2) Authors: Leibovitz A.; Wymer J.; Massey K.; Thompson F.; Nelson M.
Lung cancer-associated keratin 19 fragments: Development and biochemical characterisation of the new serum assay Enzymun-TestR CYFRA 21-1 pp. 121-121(1) Authors: Bodenmuller H.; Ofenloch-Hahnhe B.; Lane E.; Dessauer A.; Bottger V.; Donie F.
Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung pp. 121-121(1) Authors: Nakagawa H.; Yagihashi S.
Modulation of endothelial cell permeability by lung carcinoma cells: A potential mechanism of malignant pleural effusion formation pp. 121-121(1) Authors: Payne D.; Fuseler J.; Owens M.
All-trans-retinoic acid alters myc gene expression and inhibits in vitro progression in small cell lung cancer pp. 121-121(1) Authors: Kalemkerian G.P.; Jasti R.K.; Celano P.; Nelkin B.D.; Mabry M.
Constitutive synthesis of 1,25-dihydroxyvitamin D3 by a human small cell lung cancer cell line pp. 122-122(1) Authors: Mawer E.; Hayes M.; Heys S.; Davies M.; White A.; Stewart M.
RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma pp. 122-122(1) Authors: Shimizu E.; Coxon A.; Otterson G.; Steinberg S.; Kratzke R.; Kim Y.; Fedorko J.
p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas pp. 122-122(1) Authors: Walker C.; Robertson L.J.; Myskow M.W.; Pendleton N.; Dixon G.R.
Alteration in length of telomeric repeats in lung cancer pp. 122-122(1) Authors: Shirotani Y.; Hiyama K.; Ishioka S.; Inyaku K.; Awaya Y.; Yonehara S.
K-ras gene point mutation: A stable tumor marker in non-small cell lung carcinoma pp. 122-123(2) Authors: Li S.; Rosell R.; Urban A.; Font A.; Ariza A.; Armengol P.
Cyclin D1 overexpression vs. retinoblastoma inactivation: Implications for growth control evasion in non-small cell and small cell lung cancer pp. 123-123(1) Authors: Schauer I.; Siriwardana S.; Langan T.; Sclafani R.
Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma pp. 123-123(1) Authors: Tateishi M.; Ishida T.; Kohdono S.; Hamatake M.; Fukuyama Y.; Sugimachi K.
Antitumor effect of AO-90, methionine-free intravenous amino acid solution, given by total parenteral nutrition in combination with 5-fluorouracil and mitomycin C in Sato lung carcinoma-bearing rats pp. 123-123(1) Authors: Hibino Y.; Kawarabayashi Y.; Ebisu G.; Kohri H.
Less initial rejoining of X-ray induced DNA double-strand breaks in cells of a small cell (U-1285) compared to a large cell (U-1810) lung carcinoma cell line pp. 123-123(1) Authors: Cedervall B.; Sirzea F.; Brodin O.; Lewensohn R.
Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization pp. 123-124(2) Authors: Reubi J.; Schaer J.; Waser B.; Mengod G.
Effect of the dihydropyridine dexniguldipine on the epidermal growth factor- stimulated proliferation of human lung cancer cell lines pp. 124-124(1) Authors: Schuller H.; Orloff M.; Reznik G.
Cytogenetic findings in primary non-small cell lung cancer pp. 124-124(1) Authors: D'Alessandro E.; Lo Re M.; Crisci R.; Ligas C.; Coloni G.
Physical map of small cell lung cancer deletion region on short arm of human chromosome 3 (3p13-22) based on radiation fusion hybrid analysis pp. 124-124(1) Authors: Siden T.; Golembieski W.; Kumlien J.; Rohme D.; Smith D.
c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties pp. 124-124(1) Authors: Yu D.; Wang S.-S.; Dulski K.; Tsai C.-M.; Nicolson G.; Hung M.-C.
The origin of isochromosomes and their significance in tumorigenesis of human lung cancer pp. 125-125(1) Authors: Fu S.-B.; Li P.; Feng X.-L.; Liu C.-X.; Liu Q.-Z.
Expression of the glutathione S-transferases in human lung carcinoma pp. 125-125(1) Author: Guo S.-C.
A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans pp. 125-125(1) Authors: Kelsey K.; Wiencke J.; Spitz M.
Re-assessment of acidic glycosphingolipids in small-cell-lung-cancer tissues and cell lines pp. 125-125(1) Authors: Gnewuch C.; Jaques G.; Havemann K.; Wiegandt H.
Characterization of somatostatin receptors and growth inhibition by the somatostatin analogue BIM23014 in small cell lung carcinoma xenograft: SCLC-6 pp. 125-126(2) Authors: Prevost G.; Bourgeois Y.; Mormont C.; Lerrant Y.; Veber N.; Poupon M.; Thomas F.
Expression in lung tumors and genetic mapping of the novel murine protein kinase C3 pp. 126-126(1) Authors: Canzian F.; Gariboldi M.; Manenti G.; De Gregorio L.; Osada S.-I.; Ohno S.
Constitutive c-myc overexpression and P1/P2 promoter shift in a small cell cancer cell line pp. 126-126(1) Authors: Dooley S.; Wundrack I.; Welter C.; Blin N.
Karyotypic abnormalities in adenocarcinomas of the lung pp. 126-126(1) Authors: Johannsson M.; Karauzum B.; Dietrich C.; Mandahl N.; Hambraeus G.; Johansson L.
Secretion of a latent, acid activatable cathepsin L precursor by human non- small cell lung cancer cell lines pp. 126-126(1) Authors: Heidtmann H.-H.; Salge U.; Havemann K.; Kirschke H.; Wiederanders B.
Multiple NF-I-site binding factors associated with different cell-types of human lung carcinomas pp. 126-126(1) Authors: Wong Y.-C.; Bernal S.
Detection of resistance proteins in matched primary lung tumors and lymph node metastases pp. 127-127(1) Authors: Mattern J.; Volm M.
Karyotypic characterization of bronchial large cell carcinomas pp. 127-127(1) Authors: Johansson M.; Dietrich C.; Mandahl N.; Hambraeus G.; Johansson L.; Clausen P.
Genesis of squamous cell lung carcinoma: Sequential changes of proliferation, DNA ploidy, and p53 expression pp. 127-127(1) Authors: Hirano T.; Franzen B.; Kato H.; Ebihara Y.; Auer G.
Establishment of anti-idiotype monoclonal antibodies (Ab2) for specific and active immunotherapy in lung cancer patients pp. 127-127(1) Authors: Fukasawa T.; Yamaguchi Y.; Saito H.
Expression of the multidrug resistance gene (MDR1) in non-small cell lung cancer pp. 127-127(1) Authors: Abe Y.; Nakamura L.; Ota E.; Ozeki Y.; Tamai S.; Inoue H.
A study of thymidine kinase activity in lung cancer tissue pp. 127-128(2) Authors: Yusa T.; Tamiya N.; Yamaguchi Y.; Takeda T.; Ogawa T.; Kimura H.; Fujimura S.
Transforming growth factor-1 inhibits TCDD-induced cytochrome P450IA1 expression in human lung cancer A549 cells pp. 128-128(1) Authors: Vogel C.; Dohr O.; Abel J.
Immunohistochemical study of cathepsin B: Prognostic significance in human lung cancer pp. 128-128(1) Authors: Sukoh N.; Abe S.; Ogura S.; Isobe H.; Takekawa H.; Inoue K.; Kawakami Y.
Basic and clinical studies on serum cytokeratin 19 fragment assay using centocorR CYFRA 21-1 kit in patients with lung cancer pp. 128-128(1) Authors: Hamase A.; Sugimoto Y.; Maeda M.; Kitani H.; Fukuchi M.
Physical fitness of patients with small cell lung cancer pp. 128-128(1) Authors: Baracos V.; Urtasun R.; Humen D.; Haennel R.
Detection of lymph node metastases in lung cancer: Comparison of 131I-Anti-CEA-Anti-CA 19-9 immunoscintigraphy versus computed tomography pp. 128-129(2) Authors: Boilleau G.; Pujol J.-L.; Ychou M.; Faurous P.; Marty-Ane C.; Michel F.-B.
Bilateral Pancoast syndrome in a patient with metachronous primary lung cancer pp. 129-129(1) Authors: Rea F.; Mazzucco C.; Breda C.; Fiore D.; Sartori F.
Fucosyl-GM1 in small-cell lung cancer. A comparison with the tumour marker neuron-specific enolase pp. 129-129(1) Authors: Drivsholm L.; Vangsted A.; Pallesen T.; Hansen M.; Dombernowsky P.; Hirsch F.
Effect of inhaled indomethacin for bronchorrhea in a case of bronchioloalveolar carcinoma pp. 129-129(1) Authors: Kawaguchi S.; Kobayashi H.; Kanou S.; Kiryu T.; Nagata N.; Shibata H.
Immunoscintigraphy using 111In-Labelled F(AB')2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody for staging of non-small cell lung carcinoma pp. 129-129(1) Authors: Vuillez J.-P.; Moro D.; Brambilla E.; Brichon P.-Y.; Ferretti G.; Saccavini J.; Brambilla C.
Assessment of tumour necrosis and detection of mediastinal lymph node metastasis in bronchial carcinoma with technetium-99m sestamibi imaging: Comparison with CT scan pp. 129-130(2) Authors: Aktolun C.; Bayhan H.; Pabuccu Y.; Bilgic H.; Acar H.; Koylu R.
NSP-encoded reticulons are neuroendocrine markers of a novel category in human lung cancer diagnosis pp. 130-130(1) Authors: Van de Velde H.; Senden N.; Roskams T.; Broers J.; Ramaekers F.; Roebroek A.J.M.
Pleural dissemination in non-small cell lung cancer: Results of radiological evaluation and surgical treatment pp. 130-130(1) Authors: Akaogi E.; Mitsui K.; Onizuka M.; Ishikawa S.; Tsukada H.; Mitsui T.
Prognostic value of increased lung tumor tissue cathepsin B pp. 130-130(1) Authors: Ebert W.; Knoch H.; Werle B.; Trefz G.; Muley T.; Spiess E.
Superior vena cava syndrome (SVCS) in small cell lung cancer - A prognostic factor? pp. 130-131(2) Authors: Stiess J.; Kiricuta I.; Mueller G.; Bohndorf W.
A case of endobronchial carcinoid tumour treated with intratumoral injection of absolute alcohol pp. 131-131(1) Authors: Sayami P.; Singh B.; Sharma G.; Sayami G.
Serum neuron-specific enolase in small cell lung cancer: A useful tumor marker? pp. 131-131(1) Authors: Abesamis C.; Lim-Tan G.; Barzaga M.
Predictive value of exercise of testing in the evaluation of high risk patients prior to lung resection pp. 131-131(1) Authors: Pothoff G.; Wassermann K.; Winter U.; Hilger H.
Sera from some patients with antibody-associated paraneoplastic encephalomyelitis/sensory neuronopathy recognize the Ro-52K antigen pp. 131-131(1) Authors: Manley G.; Wong E.; Dalmau J.; Elkon K.; Posner J.; Furneaux H.
Miliary mesothelioma pp. 131-131(1) Author: Huncharek M.
Two cases of resected lung cancer complicated with sarcoidosis pp. 131-131(1) Authors: Tomono K.; Shibuya Y.; Sugiyama Y.; Kitamura S.; Horimi H.; Murayama F.
The effects of chemotherapy and rhG-CSF on neutrophil functions in patients with pulmonary carcinoma pp. 132-132(1) Authors: Mineshita M.; Miyazawa T.; Doi M.; Suei S.; Yamakido M.
A case of von Recklinghausen's disease and concurrent lung cancer with neurofibroma of the intrathoracic vagus nerve pp. 132-132(1) Authors: Kasashima M.; Sugiyama S.; Kitagawa M.; Tsuda M.; Tatsumura T.; Yamamoto K.
Regulation of LAK activity from pleural cavity lymphocytes and peripheral blood lymphocytes by pleural cavity macrophages in lung cancer patients without malignant effusion pp. 132-132(1) Authors: Takahashi K.; Sone S.; Uyama T.; Saito S.; Sumitomo M.; Ogura T.
Clinical features of cavitary lung cancer pp. 132-132(1) Authors: Suzuki N.; Ohno S.; Kitamura S.
Correlation between thin-section CT and histopathological structure in pulmonary adenocarcinoma. 2 Immunohistochemistry of type 4 collagen and laminin in basement membrane pp. 132-132(1) Authors: Koizumi N.; Usuda H.
Prognosis and long-term survival of non-resected non-small-cell lung cancer pp. 133-133(1) Authors: Nakano K.; Takeda K.; Tominaga N.; Hiramoto T.
Retention index of thallium-201 single photon emission computerised tomography (SPECT) as an indicator of metastasis in adenocarcinoma of the lung pp. 133-133(1) Authors: Takekawa H.; Itoh K.; Abe S.; Ogura S.; Isobe H.; Sukou N.
Prognostic factors of small-cell bronchial carcinoma pp. 133-133(1) Authors: Kelbel C.; Omid S.; Westermeier T.; Lorenz J.
Prognostic factors in lung cancer: Tables and comments pp. 133-133(1) Authors: Buccheri G.; Ferrigno D.
Assessing benefits of combining biochemical and immunological markers in patients with lung carcinoma pp. 133-133(1) Authors: Patel P.; Raval G.; Rawal R.; Patel G.; Balar D.; Shah P.
A study on nutritional and immunological status during lung cancer therapy pp. 133-134(2) Authors: Egawa S.; Yoneda T.; Narita N.
Pretreatment natural history of small cell lung cancer presenting as a solitary pulmonary nodule pp. 134-134(1) Author: Urschel J.
CYFRA 21-1 in lung cancer: Comparison with CEA, CA 125, SCC and NSE serum levels pp. 134-134(1) Authors: Molina R.; Agusti C.; Mane J.; Filella X.; Jo J.; Joseph J.
Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: Results of a multicenter trial pp. 134-134(1) Authors: Bombardieri E.; Seregni E.; Bogni A.; Ardit S.; Belloli S.; Busetto A.
Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases pp. 134-135(2) Authors: Stieber P.; Dienemann H.; Hasholzner U.; Fabricius P.; Schambeck C.; Weinzierl M.
Significance of the dosage of plasma carcinoembryonic antigen in small cell carcinoma pp. 135-135(1) Authors: Michetti G.; Bamberga M.; Pugliese C.; Belometti M.O.; Arnone P.; Minio A.
Sex hormone receptors in non-small-cell lung cancer in human beings pp. 135-135(1) Authors: Canver C.; Memoli V.; Vanderveer P.; Dingivan C.; Mentzer R.
Angiogenesis: An indicator of metastasis in non-small cell lung cancer invading the thoracic inlet pp. 135-135(1) Authors: Macchiarini P.; Fontanini G.; Dulmet E.; De Montpreville V.; Chapelier A.; Cerrina J.
Prognostic factors for survival in terminal lung cancer patients pp. 135-136(2) Authors: Schonwetter R.; Robinson B.; Ramirez G.
Role of exercise stress testing in preoperative evaluation of patients for lung resection pp. 136-136(1) Authors: Gilbreth E.; Weisman I.
Glucocorticoid responsive ACTH secreting bronchial carcinoid tumours contain high concentrations of glucocorticoid receptors pp. 136-136(1) Authors: Florkowski C.; Wittert G.; Lewis J.; Donald R.; Espiner E.
Percutaneous computed tomography-guided fine needle brachytherapy of pulmonary malignancies pp. 136-136(1) Authors: Brach B.; Buhler C.; Hayman M.; Joyner L.; Liprie S.
Glucose-induced thermogenesis in patients with small cell lung carcinoma. The effect of acute -adrenergic inhibition pp. 136-137(2) Authors: Simonsen L.; Bulow J.; Tuxen C.; Christensen N.
DNA polymerase as an independent prognostic parameter in non-small cell lung cancer - an immunohistochemical study pp. 137-137(1) Authors: Tateishi M.; Ishida T.; Hamatake M.; Fukuyama Y.; Kodono S.; Sugimachi K.
The utility of bone marrow scintigraphy and magnetic resonance imaging for non-invasive diagnosis of bone marrow pp. 137-137(1) Authors: Bathmann J.; Sigmund G.
Spontaneous regression of small cell lung cancer pp. 137-137(1) Authors: Nomura M.; Fujimura M.; Matsuda T.; Nonomura A.; Kitagawa M.; Nakamura H.
Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer pp. 137-137(1) Authors: Epstein C.; Lynch T.; Shefner J.; Wen P.; Maxted D.; Braman V.
Small cell lung cancer with paraneoplastic nephrotic syndrome pp. 137-137(1) Authors: Boon E.; Vrij A.; Nieuwhof C.; Van Noord J.; Zeppenfeldt E.
K-ras gene mutations: An unfavorable prognostic marker in stage I lung adenocarcinoma pp. 137-138(2) Authors: Silini E.; Bosi F.; Pellegata N.; Volpato G.; Romano A.; Nazari S.
A case report of granular cell tumor of the bronchus pp. 138-138(1) Authors: Kuramitsu T.; Choji T.; Matsumoto T.; Nakamura H.; Nakaki H.; Tanaka N.
Oat cell carcinoma of the lung in patients with CLL pp. 138-138(1) Authors: Singh Rahal P.; Cornelius V.
Imbalance between cathepsin B and cysteine proteinase inhibitors is of prognostic significance in human lung cancer pp. 138-138(1) Authors: Knoch H.; Werle B.; Ebert W.; Spiess E.
Three tumor-suppressor regions on chromosome 11p identified by high- resolution deletion mapping in human non-small-cell lung cancer pp. 138-138(1) Authors: Bepler G.; Garcia-Blanco M.
Sex differences in clinicopathological features of peripheral T1 adenocarcinoma of the lung pp. 138-138(1) Authors: Mizushima Y.; Kashii T.; Matsui K.; Noto H.; Miwa A.
Analysis of lectin affinity profiles in A case of adenocarcinoma of the lung associated with elevated alpha-fetoprotein in serum and sputum pp. 139-139(1) Authors: Okano R.; Sekiguchi M.; Uraguchi T.; Kuratomi Y.; Yamada S.; Sakurabayashi I.
Thirteen cases of subxiphoid pericardiotomy due to pericarditis associated with lung cancer pp. 139-139(1) Authors: Dobashi K.; Nakahashi H.; Yoshimatsu T.; Horiuchi Y.; Miyazaki Y.; Kitagawa K.
Clinical usefulness of human cytokeratin 19 fragment (CYFRA 21-1) as serum tumor marker for lung cancer pp. 139-139(1) Authors: Masaoka A.; Fukai I.; Ariyoshi Y.; Naito Y.; Kuriyama T.; Kimura Y.
The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials pp. 139-139(1) Authors: Bergman B.; Aaronson N.; Ahmedzai S.; Kaasa S.; Sullivan M.
Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastasis from small cell lung cancer pp. 140-140(1) Authors: Sorensen P.; Kristjansen P.; Wagner A.; Hansen H.
Fine needle aspiration diagnosis of benign metastasizing leiomyoma of the lung: A case report pp. 140-140(1) Authors: Hafiz M.; Wang K.-P.; Berkman A.
Benign and malignant salivary gland-type mixed tumors of the lung: Clinicopathologic and immunohistochemical study of eight cases pp. 140-140(1) Authors: Moran C.; Suster S.; Askin F.; Koss M.
Alpha-amylase in resectable lung cancer pp. 140-140(1) Authors: Lenler-Petersen P.; Grove A.; Brock A.; Jelnes R.
Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: A prospective study pp. 140-141(2) Authors: Casson A.; McCuaig S.; Craig I.; Ayed A.; Inculet R.; Kerkvliet N.
Lithium oxybutyrate administration in lung cancer patients to improve results in early postoperative period pp. 141-141(1) Authors: Leonenkov V.; Dunaevsky I.; Semigolovsky N.; Barchuk A.; Evtyukhin A.; Kostyuchenko A.
The clamshell incision: An improved approach to bilateral pulmonary and mediastinal tumor pp. 141-141(1) Authors: Bains M.; Ginsberg R.; Jones W.; McCormack P.; Rusch V.; Burt M.
Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection pp. 141-141(1) Authors: Ichinose Y.; Yano T.; Yokoyama H.; Inoue T.; Asoh H.; Tayama K.
Pulmonary function after sleeve lobectomy pp. 141-141(1) Authors: Khargi K.; Duurkens V.; Verzijlbergen F.; Huysmans H.; Knaepen P.
Surgical results and prognostic factors of pathologic N1 disease in non- small-cell carcinoma of the lung - Significance of N1 level: Lobar or hilar nodes pp. 141-142(2) Authors: Yano T.; Yokoyama H.; Inoue T.; Asoh H.; Tayama K.; Ichinose Y.
Surgery for Stage IIIa-N2 non-small cell lung cancer pp. 142-142(1) Author: Mountain C.
The results of combination chemotherapy with etoposide, ifosfamide and cisplatin in patients with lung cancer (A preliminary report) pp. 142-142(1) Authors: Berk A.; Ozet A.; Arpaci F.
Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor pp. 142-142(1) Authors: Nichols C.; Fox E.; Roth B.; Williams S.; Loehrer P.; Einhorn L.
Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony- stimulating factor: A phase I study with apparent activity in non-small-cell lung cancer pp. 142-143(2) Authors: Krigel R.; Palackdharry C.; Padavic K.; Haas N.; Kilpatrick D.; Langer C.
A prospective randomized clinical trial comparing preventive and conventional use of rhG-CSF in lung cancer patients receiving chemotherapy pp. 143-143(1) Authors: Nakamura H.; Yamaji Y.; Fujita J.; Takigawa K.; Mori Y.; Kamei T.
Reduced levels of topoisomerase II and II in a multidrug-resistant lung-cancer cell line pp. 143-143(1) Authors: Evans C.; Mirski S.; Danks M.; Cole S.
Combination chemotherapy with cyclophosphamide, epirubicin and etoposide in small cell lung cancer pp. 143-143(1) Authors: Jassem J.; Karnigka-Mlodkowska H.; Jassem E.; Slupek A.; Zych J.; Wiatr E.
Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer pp. 143-144(2) Authors: Skarlos D.; Samantas E.; Kosmidis P.; Fountzilas G.; Angelidou M.; Palamidas P.
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study pp. 144-144(1) Authors: Abratt R.; Bezwoda W.; Falkson G.; Goedhals L.; Hacking D.; Rugg T.
Role of DT-diaphorase as a determinant of sensitivity to mitomycin analogues in non-small cell lung cancer cell lines pp. 144-144(1) Authors: Bando T.; Kasahara K.; Shibata K.; Nakatsumi Y.; Fujimura M.; Matsuda T.
Cisplatin-5-fluorouracil in small cell lung cancer. A phase II study in 109 patients pp. 144-144(1) Authors: Morere J.; Durana A.; Tcherakian F.; Boaziz C.; Valeyre D.; Battesti J.
A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I pp. 144-145(2) Authors: Prost S.; Riou G.
A four-drug combination chemotherapy with cisplatin, mitomycin, vindensine and 5-fluorouracil pp. 145-145(1) Authors: Klastersky J.; Sculier J.P.; Ries F.; Dabouis G.; Libert P.; Schmerber J.
Transient neutropenia after intravenous injection of vindesine in patients with lung cancer pp. 145-145(1) Authors: Aoshiba K.; Nagai A.; Ueno H.; Konno K.
Chemotherapy vs supportive care in advanced non-small-cell lung cancer: Results of a meta-analysis of the literature pp. 145-145(1) Authors: Marino P.; Pampallona S.; Preatoni A.; Cantoni A.; Invernizzi F.
Successful treatment of refractory extensive small cell lung cancer by oral etoposide pp. 145-145(1) Authors: Fujii S.; Iwabuchi K.
Clinical effects and safety of granisetron administration against CDDP chemotherapy in lung cancer pp. 145-146(2) Authors: Hamada T.; Kuwahara T.; Ida M.; Hayasaka S.; Yoshinaga T.; Kawano S.
Activity of docetaxel (Taxotere) in small cell lung cancer pp. 146-146(1) Authors: Smyth J.; Smith I.; Sessa C.; Schoffski P.; Wanders J.; Franklin H.
Platinum-based chemotherapy in non-small cell lung cancer: The experience of the European Organization for the Research and Treatment of Cancer pp. 146-146(1) Authors: Van Zandwijk N.; Dalesio O.
Small cell lung cancer in the elderly pp. 146-146(1) Authors: Byrne A.; Carney D.
Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: A prospective randomized phase III trial pp. 146-146(1) Authors: Gatzemeier U.; Pawel J.; Laumen R.; Hossfeld D.; Neuhauss R.
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study pp. 146-147(2) Authors: Kosmidis P.; Samantas E.; Fountzilas G.; Pavlidis N.; Apostolopoulou F.; Skarlos D.
Carboplatin for small cell lung cancer: Progress toward greater efficacy and reduced toxicity pp. 147-147(1) Authors: Raghavan D.; Perez R.; Creaven P.; Takita H.; Loewen G.; Vaickus L.
Etoposide in the treatment of elderly/poor-prognosis patients with small-cell lung cancer pp. 147-147(1) Authors: Carney D.; Byrne A.
Alpha interferon, leucovorin, and 5-fluorouracil (ALF) in advanced cancer: Results of a dose-finding study and evidence of activity in non-small cell lung cancer pp. 147-147(1) Authors: Quan W.; Madajewicz S.; Smith M.; Skeel R.
Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer pp. 147-147(1) Authors: Rudd R.; Allen R.; Berille J.; Spiro S.; Trask C.; Souhami R.L.
External radiotherapy for Pancoast tumor pp. 147-147(1) Authors: Hayashi S.; Sekiguchi K.; Nakazawa M.; Sougawa M.; Yamashita T.
A randomized controlled postoperative adjuvant chemotherapy trial of CDDP + VDS + UFT and UFT alone in comparison with operation only for non-small cell lung carcinomas - Second study pp. 147-148(2) Author: Tomita M.
Docetaxel (TaxotereR) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG) pp. 148-148(1) Authors: Cerny T.; Kaplan S.; Pavlidis N.; Schoffski P.; Epelbaum R.; Van Meerbeek J.
Inhibition of growth of human small cell lung cancer by bromocriptine pp. 148-148(1) Authors: Ishibashi M.; Fujisawa M.; Furue H.; Maeda Y.; Fukayama M.; Yamaji T.
A Phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors pp. 148-148(1) Authors: Saltz L.; Kemeny N.; Schwartz G.; Kelsen D.
Vinorelbine monochemotherapy in non-small-cell lung cancer: Experience in patients with low performance status pp. 148-148(1) Authors: Masotti A.; Zannini G.; Poggi R.; Morandini G.C.
The role of chemotherapy in the treatment of stage III non-small-cell lung cancer (NSCLC) pp. 148-149(2) Authors: Manegold C.; Drings P.
Therapeutic evaluation of cisplatin, vindesine, and mitomycin C therapy in advanced non-small-cell lung cancer pp. 149-149(1) Authors: Okada K.; Koizumi T.; Hayano T.; Hayasaka M.; Yaguchi N.; Hachiya T.
Experimental evaluation of combination chemotherapy with UFT and cisplatin for the lung cancer pp. 149-149(1) Authors: Uchida J.; Satake H.; Saito H.; Nakano K.; Takeda S.; Unemi N.
Phase I clinical study of KW-2307 combined with cisplatin in non-small cell lung cancer patients pp. 149-149(1) Authors: Yamamoto M.; Ariyoshi Y.; Hasegawa K.; Kobayashi K.; Fukuoka M.; Kurita Y.
Mitomycin C etoposide and vinorelbine (MEV II) in the treatment of metastatic stage IV non small cell lung cancer pp. 149-149(1) Authors: Gridelli C.; Rossi A.; Palazzolo G.; Pepe R.; Airoma G.; Incoronato P.
Dominated and resistant subpopulation causes regrowth after response to 1,3-Bis(2-chloroethyl)-1-nitrosourea treatment of a heterogeneous small cell lung cancer xenograft in nude mice pp. 150-150(1) Authors: Aabo K.; Roed H.; Vindelov L.; Spang-Thomsen M.
Small-cell lung cancer: Comparison to a weekly chemotherapy with drugs with a standard chemotherapy pp. 150-150(1) Authors: Sculier J.-P.; Paesmans M.; Bureau G.; Dabouis G.; Libert P.; Vandermoten G.
A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer pp. 150-150(1) Authors: Rosell R.; Maestre J.; Font A.; Moreno I.; Molina F.; Milla A.
Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer pp. 150-150(1) Authors: Fischer J.; Manegold C.; Bulzebruck H.; Vogt-Moykopf I.; Drings P.
An ongoing randomized study of neoadjuvant chemotherapy in resectable non-small cell lung cancer pp. 151-151(1) Authors: Depierre A.; Milleron B.; Lebeau B.; Moro D.; Chastang C.; Jacoulet P.
Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: A phase II study in stage IIIB-IV non-small cell lung cancer pp. 151-151(1) Authors: Baldini E.; Tibaldi C.; Chella A.; Angeletti C.; Romanini A.; Andrei A.
Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer pp. 151-151(1) Authors: Palackdharry C.; Krigel R.
Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer pp. 151-151(1) Authors: Perez E.; Gandara D.
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments pp. 151-151(1) Authors: Jensen P.; Sorensen B.; Sehested M.; Grue P.; Demant E.; Hansen H.
Subcutaneous heparin treatment increases survival in small cell lung cancer pp. 152-152(1) Authors: Lebeau B.; Chastang C.; Brechot J.-M.; Capron F.; Dautzenberg B.; Delaisements C.
Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells pp. 152-152(1) Authors: Pedrazzoli P.; Bacciocchi G.; Bergamaschi G.; Cazzola M.; Danova M.; Gibelli N.
Early Phase II clinical study of KW-2307 in patients with lung cancer pp. 152-152(1) Authors: Furuse K.; Ohta M.; Fukuoka M.; Kurita Y.; Kobayashi K.; Hasegawa K.
Carboplatin combined etoposide in the treatment of lung cancer pp. 152-152(1) Author: Su D.-H.
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer pp. 152-152(1) Authors: Fossella F.; Lee J.S.; Murphy W.; Lippman S.; Calayag M.; Pang A.
Phase II trial of docetaxel in patients with stage III and IV non-small- cell lung cancer pp. 152-153(2) Authors: Francis P.; Rigas J.; Kris M.; Pisters K.; Orazem J.; Woolley K.
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma pp. 153-153(1) Authors: Rusch V.; Saltz L.; Venkatraman E.; Ginsberg R.; McCormack P.; Burt M.
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer pp. 153-153(1) Authors: Loprinzi C.; Goldberg R.; Su J.; Mailliard J.; Kuross S.; Maksymiuk A.
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the cancer and leukemia group B pp. 153-153(1) Authors: Kosty M.; Fleishman S.; Herndon J.; Coughlin K.; Kornblith A.; Scalzo A.
Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer pp. 153-154(2) Authors: Shinkai T.; Arioka H.; Kunikane H.; Eguchi K.; Sasaki Y.; Tamura T.
c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung pp. 154-154(1) Authors: Li Z.-H.; Zheng J.; Weiss L.; Shibata D.
Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: Preliminary report of a French multicentre phase II trial pp. 154-154(1) Authors: Riviere A.; Le Cesne A.; Berille J.; Baio S.; Le Chevalier T.
Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer pp. 154-154(1) Authors: Pujol J.-L.; Monnier A.; Berille J.; Cerrina M.-L.; Douillard J.-Y.; Riviere A.
Cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of metastatic non-small cell lung cancer: Limited activity of an aggressive chemotherapy regimen pp. 155-155(1) Authors: Murren J.; Durivage H.; Rosenberg A.; Chen Y.; Del Prete S.; Murphy G.
Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: An Eastern Cooperative Oncology Group study pp. 155-155(1) Authors: Bonomi P.; Finkelstein D.; Chang A.
VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer pp. 155-155(1) Authors: Evans W.; Stewart D.; Shepherd F.; Logan D.; Goss G.; Maroun J.
Treatment-related deaths in small cell lung cancer trials: Can patients at risk be identified? pp. 155-155(1) Authors: Stephens R.; Girling D.; Machin D.
Neo-adjuvant chemotherapy for non-small cell locally advanced bronchogenic cancer pp. 155-155(1) Authors: Pujol J.-L.; Daures J.-P.; Godard P.; Michel F.
Neoadjuvant therapy: A novel and effective treatment for stage IIIb non-small cell lung cancer pp. 156-156(1) Authors: Rusch V.; Albain K.; Crowley J.; Rice T.; Lonchyna V.; McKenna R.
Infusional cisplatin and etoposide in the treatment of stage III-B and IV non-small cell lung cancer: A well tolerated regimen pp. 156-156(1) Authors: Glynn P.; Higby D.; Moriarty E.; Ficalora M.; Volpe B.; Koletsky A.
Alternating irradiation and chemotherapy in Stage III A and B nonsmall cell lung cancer: Report of a cancer and leukemia group B phase II study 8636 pp. 156-156(1) Authors: Seagren S.; Herndon J.; Baeker J.; Boles M.; Chung C.; Green M.
A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer pp. 156-156(1) Authors: Scarantino C.W.; McCunniff A.J.; Evans G.; Young C.W.; Paggiarino D.A.
Combination chemotherapy and radiation therapy in lung cancer pp. 156-156(1) Author: Sause W.
Intensive combined-modality therapy in small cell lung cancer pp. 157-157(1) Authors: Thatcher N.; Lorrigan P.; Burt P.; Stout R.
Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer pp. 157-157(1) Authors: Pisters K.; Kris M.; Gralla R.; Hilaris B.; McCormack P.; Bains M.
Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer pp. 157-157(1) Authors: Kubota K.; Furuse K.; Kawahara M.; Kodama N.; Yamamoto M.; Ogawara M.
Combined treatment in superior sulcus tumors pp. 157-157(1) Authors: Martinez-Monge R.; Herreros J.; Aristu J.; Aramendia J.; Azinovic I.
Superior sulcus tumors: Combined modality pp. 157-157(1) Authors: Fuller D.; Chambers J.
Multimodality therapy for non-small-cell lung cancer pp. 158-158(1) Authors: Lilenbaum R.; Green M.
Surgery after radiochemotherapy for stage III lung cancer: Postoperative complications and late results pp. 158-158(1) Authors: Tavecchio L.; Ravasi G.; Bedini A.; Gramaglia A.; Milani F.
Lung cancer pp. 158-158(1) Authors: Gilliland F.; Samet J.
Nonoperative management of non-small cell lung cancer: The current Cancer and Leukemia Group B experience pp. 158-158(1) Authors: Green M.; Kosty M.; Muscato J.; Graziano S.; Dillman R.; Clamon G.
The treatment of non-small cell lung cancer: Current perspectives and controversies, future directions pp. 158-158(1) Author: Bunn P.
Lung cancer - Development, diagnosis, therapy, prognosis pp. 159-159(1) Authors: Zochbauer S.; Krajnik G.; Huber H.
A clinical therapeutic results on small cell lung cancer pp. 159-159(1) Authors: Kim E.; Lee S.; Huh W.; Kim H.; Jo J.; Kim M.
Small cell lung cancer treatment pp. 159-159(1) Authors: Lebeau B.; Schuller M.
Treatment of lung cancer in 1994 pp. 159-159(1) Author: Vincent M.
Future directions in the treatment of non-small cell lung cancer pp. 159-159(1) Author: Shepherd F.
Japanese doctors' preferred treatment choices for their hypothetical non- small cell lung cancer: How they would wish to be treated pp. 159-160(2) Authors: Motohiro A.; Hirota N.; Komatsu H.; Yanai N.
Patterns of care and survival in non small cell lung cancer: 15 years' experience in a general hospital pp. 160-160(1) Authors: Clerici M.; Panvini D.; Torri V.; Colombo F.; Luporini G.; Tinazzi A.
Psychosocial stress of bronchial-carcinoma patients and their expectations of oncological indoor aftercare pp. 160-160(1) Authors: Fischer H.; Freeman C.; Kugelen G.
Shopping cart
RSS for latest issue
Print this page
Print this page
Print this page